Literature DB >> 16729375

ADHD drugs and cardiovascular risk.

Marsha D Rappley, John W Moore, Deborah Dokken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16729375

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

2.  Cardiac risk assessment before the use of stimulant medications in children and youth.

Authors:  S A Bélanger; A E Warren; R M Hamilton; C Gray; R M Gow; S Sanatani; J M Côté; J Lougheed Frcpc; J Leblanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

Review 3.  Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Authors:  Gary Stiefel; Frank M C Besag
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 4.  Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Authors:  A E Warren; R M Hamilton; S A Bélanger; C Gray; R M Gow; S Sanatani; J-M Côté; J Lougheed; J LeBlanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Can J Cardiol       Date:  2009-11       Impact factor: 5.223

5.  Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death.

Authors:  Frank M C Besag
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.